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Financial Impact of Complex Cancer 
Surgery in India: A Study of Pancreatic 
Cancer
INTRODUCTION
The incidence of cancer is on the rise globally. 
In India alone, 700,000 deaths are attributed to 
cancer every year.1,2 This rise in cancer incidence 
translates into increased health care costs in 
terms of treatment, lost earnings, and the reha-
bilitation of patients, which can be protracted in 
cancer care. This problem of high health care 
expenditure is more pronounced in emerging 
powers such as India, where insurance cover-
age is not comprehensive and government total 
health expenditure (1.4% of GDP in 2014)3 is 
limited. Only 25% of India’s population is cov-
ered under any sort of health insurance, which 
includes all forms of private, employer-based, 
and government-sponsored health insurance 
schemes.4 As a result, a cancer diagnosis has 
a huge impact on personal finances, and with 
increasing needs for complex cancer surgery, 
the cost impact is set to rise, necessitating a 
greater understanding of the total economic 
impact in national settings.5,6
Surgeries for pancreatic cancer, one of the bell-
wether cancers for complex tertiary care, are 
major procedures, with their own set of compli-
cations. Increased morbidity is associated with 
increased costs of treatment because the costs 
incurred to treat complications further add to 
personal and institutional costs.7 A recent series 
from India showed that despite excellent results 
and a low mortality rate, one third of patients 
undergoing pancreatico-duodenectomy (PD) have 
significant morbidity.8
From a public health as well as a policy per-
spective, it is imperative to have reliable data 
on the economic burden of cancer, particularly 
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on complex and expensive surgical proce-
dures undertaken in the public sector, so that 
evidence-based decisions regarding allocation 
of resources to public health programs can be 
made. Hence, the aim of this study was to pro-
vide data regarding the economic burden faced 
by patients undergoing PD, to aid in the making 
of policy decisions and in planning, as well as 
to provide benchmarks for the prioritization of 
resources and sufficient protection against cat-
astrophic expenditure.
METHODS
Data were obtained prospectively between Jan-
uary 2014 and June 2015 to assess the costs 
incurred for PD at Tata Memorial Centre, India’s 
major tertiary cancer center. The center is a 
public entity and receives partial support from 
the Government of India for research and treat-
ment. The study was approved by the institu-
tional review board of Tata Memorial Centre 
after the board reviewed the study protocol and 
the feasibility of the study. A questionnaire was 
developed on the basis of a review of previous 
studies that attempted to measure the expendi-
ture incurred by patients while accessing treat-
ment, covering all the categories under which 
patients were expected to incur expenses for 
surgical care. The questionnaire was analyzed 
by experts familiar with the subject and by our 
institutional review board, which reviewed all the 
questionnaire items for comprehensiveness and 
readability. The questionnaire was edited on the 
basis of their recommendations. This study was 
objective in nature (ie, patients stated the amount 
they paid for a particular service); in this type of 
study answers may vary greatly, and therefore, 
we expected high variability in the data. 
The Comprehensive Score for Financial Toxicity 
tool for measuring the financial distress expe-
rienced by patients with cancer has been vali-
dated in a study conducted in the United States. 
Although validated and largely applicable to 
the Indian population, the study was published 
in June 2014, whereas data collection for this 
study commenced in January 2014; hence, 
we were unable to use this tool for the study.9 
The questionnaire was distributed to patients 
who underwent a PD, and was to be completed 
either by the patient him- or herself or by any 
family member who was knowledgeable about 
hospitalization expenses. The time frame during 
which expenses were considered was from the 
first hospital visit to postoperative recovery (ie, 
until the day of discharge) and included charges 
of preoperative investigations. The questionnaire 
contained questions on expenditure during each 
stage of disease management, including base-
line and preoperative blood tests, radiologic 
imaging, surgical costs including consumables, 
surgery charges, and intensive care unit and 
room charges until the day of discharge. The cost 
of chemotherapy and radiotherapy and any type 
of indirect cost were not included in the study. 
Informed consent was obtained from all patients 
after they had reviewed the patient information 
leaflet. Patients were asked to post back the 
questionnaires after discharge or to hand them 
over to the physician during their first follow-up 
visit. For patients who failed to return the ques-
tionnaire, telephonic interviews were conducted 
with either the patient or a first-degree relative.
To assess the extent of financial burden on the 
households in our study, we calculated the inci-
dence of catastrophic expenditure among the 
households in which a member had undergone 
PD. Catastrophic expenditure was calculated by 
assessing the percentage of households whose 
out-of-pocket (OOP) health payments (Hexp) 
exceeded a certain percentage (Zcat) of the 
household’s total prepayment annual income 
(x), used as a proxy for the household’s capacity 
to pay. Therefore, OOP expenditure is consid-
ered catastrophic when Hexp/x exceeds a spec-
ified threshold (ie, Zcat).10,11 When households’ 
total annual income is used as a denominator 
for calculating Zcat, the most common threshold 
set is 10%; hence, the catastrophic threshold 
for our study was set at 10%.10,12-14 The underly-
ing ideology in setting the threshold for defining 
catastrophic expenditure is that if a household’s 
expenditure on health care is more than the 
threshold, the household will have to reduce 
its expenditure on other subsistence needs 
because of the need to pay for health care. This 
may push households into poverty or deepen 
their existing poverty.10,11,15 Currency conversion 
was at the rate of $US1 = 68 Indian Rupee (INR; 
Rs) as of January 1, 2015. The data on expenses 
have been mentioned in both the crude US 
dollar value and the purchasing power parity 
(PPP)–corrected value for ease of understand-
ing.16 PPP conversions were performed accord-
ing to standard protocols for January 1, 2015.17 
PPP reflects a country’s ability to purchase a 
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standardized set of goods and services, facili-
tating comparisons across countries. Thus, the 
PPP standardizes costs across countries using 
a common reference point: the US dollar. The 
US dollar, as the reference currency, is equal to 
unity. Reporting cost information in a common 
currency is a standard approach in health eco-
nomics and one that is recommended by WHO.
RESULTS
The analysis was based on data collected from 
98 patients (mean age, 54.5 years [range, 10 
to 87 years]) who underwent PD; 66.3% of the 
respondents were male; 45.9% were public, 
30.6% semiprivate, and 23.5% private ward 
admissions. Table 1 documents the demo-
graphic details of the patients.
Among the 98 patients, only 29.6% had insur-
ance coverage, whereas the rest had to make 
OOP payments for hospitalization. It was observed 
that, if segregated according to the type of ward 
to which the patient was admitted, 40% of those 
admitted to a semiprivate ward had insurance 
coverage compared with 30.4% of those admit-
ted to private and 22.2% to public wards. Among 
those who were insured, 41.4% had private 
insurance, 31% had government insurance, and 
27.6% had employer-based insurance.
Table 2 lists the types of insurance coverage 
among the insured patients, segregated by 
the ward to which they were admitted. Among 
patients in public wards, 90% were covered by a 
government-based insurance scheme.
The mean household income of patients in 
semiprivate wards was slightly higher than that 
of those in private wards; however, on assessing 
the median, we see that those admitted in the 
public ward had the lowest family income.
The expenditure incurred by patients differed 
according to different parameters such as 
type of ward, insurance coverage, presence of 
complications, and sex. Table 3 lists the mean 
and median expenditure incurred by patients in 
each subcategory.
The mean expenditure of patients admitted to 
private and semiprivate wards was significantly 
higher (P < .001) than the mean expenditure 
of those admitted to public wards. Although the 
mean expenditure of those with insurance was 
slightly higher than those without insurance, this 
difference was not statistically significant.
The mean expenditure for patients with com-
plications was significantly higher (P < .005), 
at Rs.368,095.28 (US$5,413 crude; US$92,649 
PPP corrected) than that of those without 
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Table 1. Patient Characteristics (n = 98)
Patient Characteristic No. (%)*
Age, years
Mean (range) 54.5 (10-87)
0-50 20 (20.4)
51-60 37 (37.8)
61-70 21 (21.4)
> 70 20 (20.4)
Sex
Male 65 (66.3)
Female 33 (33.7)
Ward admission
Public 45 (45.9)
Semiprivate† 30 (30.6)
Private† 23 (23.5)
Insurance coverage
Self-paying 69 (70.4)
Insured 29 (29.6)
Employer-based 8 (27.6)
Government‡ 9 (31.0)
Private 12 (41.4)
Recovery from surgery§
No complications 49 (50)
Complications 49 (50)
*Unless indicated otherwise.
†Semiprivate: wards in which two self-paying or insured 
patients are treated in a single room partitioned by a curtain for 
privacy; private: one self-paying or insured patient is treated in 
a single room.
‡There are three central government and one state govern-
ment insurance schemes: central government health scheme, 
employees’ state insurance scheme, Rashtriya Swasthya Bima 
Yojna, and Rajiv Gandhi Jeevandayee Arogya Yojana. Some 
patients also had employer-specific and private insurance.
§Complications associated with pancreatico-duodenectomy 
were documented prospectively according to the International 
Study Group of Pancreatic Surgery guidelines.15,18,19
Table 2. Segregation of Type of Insurance by Ward
Type of 
Admission
Employer-
Based 
Insurance,  
No. (%)
Government 
Insurance,  
No. (%)
Own Private 
Insurance,  
No. (%) Total
Public 1 (10) 9 (90) 0 (0) 10
Semiprivate 6 (50) 0 (0) 6 (50) 12
Private 1 (14.3) 0 (0) 6 (85.7) 7
Total 8 (27.6) 9 (31) 12 (41.4) 29
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complications, which was Rs.223,263.85 (US$3, 
283 crude; US$56,192 PPP corrected).18-20 
The mean expenditure for male patients was 
found to be higher, at Rs.315,639.8 (US$4,642 
crude; US$79,452 PPP corrected) than that of 
female patients, although no statistical signifi-
cance could be established.
As seen in Table 4, if a comparison is made 
between the mean expenditure for patients with 
and without insurance admitted to the differ-
ent wards, we see that the mean expenditure 
for those with insurance was lower than that 
of those without insurance in all ward catego-
ries, although this difference is not seen in the 
median values.
In the total sample, 76.5% faced a catastrophic 
impact when the catastrophic threshold was set 
at 10% of annual household expenditure. Table 
5 lists the patients facing a catastrophic impact, 
segregated on the basis of the ward to which 
they were admitted.
The percentage of patients suffering a cata-
strophic impact was highest among those in 
semiprivate wards, at 86.7%, followed by those 
in public and private wards. If a comparison 
is made regarding the incidence of financial 
catastrophe between those with and those with-
out insurance, we see that those without insur-
ance had a significantly higher risk of facing 
a catastrophic impact compared with those 
with insurance (P < .001). Thirty-eight percent 
of those with insurance underwent financial 
catastrophe compared with 93% of those with-
out insurance.
DISCUSSION
In our study, the total mean expenditure for sur-
gery was found to be Rs.295,679.57 (US$4,348 
crude; US$74,420 PPP corrected). This mean 
amount was significantly higher for patients 
admitted to private wards and for those with 
complications. The average amount found in 
our study is marginally higher than that found in 
other studies that have analyzed expenditure 
related to other cancer-related surgeries. Although 
Mukhopadhyay et al 21found the average expendi-
ture for radiotherapy at All India Institute of Med-
ical Sciences to be Rs.36,812, another study, by 
Nair et al,22 which assessed the expenditure by 
patients receiving cancer treatment in six gov-
ernment hospitals in India, found that although 
33.6% of the patients reported receiving treat-
ment free of cost, the average cost of investiga-
tions for the remaining patients was Rs.16,739 
and for treatment was Rs.41,311. This may be 
because our hospital is a tertiary cancer center 
and therefore patients with advanced disease 
come here for complex treatment, and because 
PD is a major complex surgery, the cost is often 
higher than for other cancer surgeries.
The relationship between advanced disease and 
increased expenditure has been documented 
by other studies as well. Nair et al22 found that 
expenditure in superspecialty hospitals was 
higher. Another study in Delhi found that the 
average expenditure for treatment of oral can-
cer was Rs.1,49,995 for patients in stage I, 
Rs.1,41,621 for stage II, and Rs.1,82,859 for 
stage III. The expenditure incurred for treatment 
of patients with stage III disease was significantly 
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Table 3. Mean and Median Expenditures Incurred by Patients (in INR)
Characteristic Mean INR (Crude US$) Median INR (Crude US$)
Ward
Public (n = 45) 131,411.50 (1,932.50) 92,562.00 (1,361.20)
Semiprivate (n = 30) 401,060.06 (5,897.90) 343,824.50 (5,056.20)
Private (n = 23) 479,620.65 (7,053.20) 393,745.00 (5,790.30)
Coverage
Insured (n = 29) 305,470.13 (4,492.20) 295,864.00 (4,350.00)
Not Insured (n = 69) 291,564.69 (4,287.00) 256,121.00 (3,766.40)
Complications
Yes (n = 49) 368,095.28 (5,413.00) 342,986.00 (5,043.00)
No (n = 49) 223,263.85 (3,283.20) 224,234.00 (3,297.50)
Sex
Male (n = 65) 315,639.80 (4,641.70) 296,203.00 (4,355.90)
Female (n = 33) 256,363.96(3,770.00) 256,121.00 (3,766.40)
Total (n = 98) 295,679.57 (4,348.20) 279,806.00 (4,114.70)
Abbreviation: Indian Rupee (INR)
Table 4. Mean and Median Expenditures Incurred by Patients on the Basis of Insurance and Ward (in Indian rupees)
Ward
Insured Self-Paying
No. Mean (Crude US$) Median (Crude US$) No. Mean (Crude US$) Median (Crude US$)
General 10 94,753 (1,393) 95,548 (1,405) 35 141,885 (2,087) 92,226 (1,356)
Semiprivate 12 385,201 (5,665) 358,582 (5,273) 18 411,632 (6,053) 339,069 (4,986)
Private 7 469,812 (6,909) 477,598 (7,024) 16 483,911 (7,116) 374,363 (5,505)
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higher than for those with stage I and stage II dis-
ease.23 A study by Han et al24 in China also found 
significantly higher treatment costs for patients 
with stage III and IV compared with those with 
stage I and II disease. They also found that treat-
ment costs were higher in male patients than in 
female patients, which is similar to the findings 
of our study, although not statistically significant. 
Another interesting finding was that the cost per 
patient was found to be lower for patients with 
health insurance than for those without insur-
ance. This is in contrast to the findings of our 
study, in which the mean expenditure of those 
with insurance was slightly higher than that of 
those without insurance, even though no statisti-
cal relationship could be established.
An increasing body of research highlights the 
adverse effects of OOP health expenditure on a 
patient’s quality of life, compliance, and cancer 
outcomes.25,26 Although our study did not look at 
long-term patient outcomes and treatment com-
pliance because the time frame for the study was 
from the first hospital visit to postoperative recov-
ery, it may be assumed that high OOP expendi-
ture may serve as a deterrent to accessing health 
care, because patients may avoid mandated 
treatment for fear of incurring costs.27-30
It should be noted that our study did not take 
into consideration the costs associated with che-
motherapy and radiation, indirect costs, and 
opportunity costs. In many cases, these costs 
may well exceed the cost of the surgery itself. If 
our study had included the cost associated with 
radiation and chemotherapy and indirect costs, 
the mean cost incurred by the patients would 
be much higher. Approximately 50% to 60% 
of patients receive adjuvant chemotherapy with 
gemcitabine and, given the negative results from 
adjuvant chemoradiation, only selected patients 
with margin-positive disease received adjuvant 
chemoradiation..31,32
How, then, do our findings compare with other 
site-specific cancer costs in other low- and middle- 
income countries? A study conducted in Viet-
nam that assessed the direct costs associated 
with breast cancer found the average amount to 
be US$975 (US$16,688, PPP corrected). The 
greatest proportion of this expenditure (64.9% 
of the total) was attributed to chemotherapy.33 
Patients in our study would also have incurred 
significant costs before coming to hospital. 
The study by Mukhopadhyay et al 21found that 
patients spent an average of Rs.14,597 even 
before going to All India Institute of Medical 
Sciences All India Institute of Medical Sciences 
for treatment. Nair et al22 found indirect costs 
incurred for transport, companions, and so 
forth, to be, on average, Rs.27,248, whereas the 
opportunity cost (ie, loss of wages because of ill-
ness) was Rs.18,165.
India spends approximately 4.6% of its GDP 
on health (30% financed by the government 
and 70% financed privately), compared with 
14% in Maldives, 29% in Bhutan, 53% in Sri 
Lanka, 31% in Thailand, and 61% in China. 
OOP expenditure by people seeking health care 
still remains the predominant source of private 
health finance in India, accounting for 71% of 
private health expenditure.3,34,35
Only 29.6% of the respondents in our study had 
insurance. Most of those admitted to a public 
ward were covered by government insurance 
schemes, whereas for those in private wards, 
voluntary private insurance was found to be the 
most common form of insurance. Various gov-
ernment health schemes have been launched 
by both the state and federal governments to 
subsidize cancer care for citizens, with aid rang-
ing from INR 30,000 (US$441 crude; US$7,551 
PPP corrected) to INR 150,000 (US$2,205 crude; 
US$37,783 PPP corrected). These schemes are 
for families living in poverty, and access to them 
requires government-issued proof of income 
such as the Below Poverty Line card or the Yel-
low or Orange ration card. A Below Poverty Line 
card is provided on the basis of census, to iden-
tify poor households eligible for social support, 
whereas ration cards are segregated according 
to family income: those with an annual family 
income < INR 15,000 (US$220 crude; US$378 
PPP corrected) are given Yellow cards, and 
those with an annual family income of up to INR 
100,000 (US$1,471 crude; US$25,169 PPP 
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Table 5. Catastrophic Impact Segregated by Type of 
Ward
Ward
Patients Who Suffered 
Catastrophic Impact at 
the 10% Threshold, No. 
(%)
Public (n = 45) 34 (75.6)
Semiprivate (n = 30) 26 (86.7)
Private (n = 23) 15 (65.2)
Total (n = 98) 75 (76.5)
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corrected) are given Orange ration cards. Fam-
ilies above this income bracket are expected to 
opt for private health insurance and some may 
be covered by employer-based health insur-
ance. Only 9% of our study sample had used 
government-sponsored schemes. Access to 
government-sponsored schemes has been ques-
tioned because eligible beneficiaries have not 
been able to use the schemes because of a lack 
of awareness, difficulty in obtaining the neces-
sary documents for enrolment, and insufficient 
coverage under the scheme.36-38 Low insurance 
coverage in the population may be viewed as a 
barrier to accessing health care. Hoang et al33 
also found that an absence of health insurance 
was one of the main factors limiting uptake. In 
our study, only 38% of those with insurance 
underwent financial catastrophe, compared with 
93% of those without insurance. So ideally, had 
a larger proportion of our sample been covered 
by insurance, the incidence of financial catastro-
phe would have been much lower. According 
to different estimates, approximately 40 to 60 
million people in India become impoverished 
annually because of unexpected health expendi-
ture,39-42 which could be attributed to the lack of 
insurance coverage.
The increasing use of technology in investi-
gations and the high cost of imported medical 
equipment and patented drugs have been piv-
otal in increasing the cost of cancer treatment. 
A dearth of adequate screening programs for 
early diagnosis and a lack of awareness among 
patients also lead to cancer being diagnosed at 
later stages, which often leads to an increase in 
expenditure because of the need for advanced 
health care measures.
In our study sample, 76.5% faced a catastrophic 
impact on the household because of expenditure 
on health care. Although the mean expenditure 
was highest in the private ward, the catastrophic 
impact was higher in patients in semiprivate and 
public wards. The higher income levels of those 
admitted to private wards may be the reason 
for this. A study conducted by Engelgau et al43 
in 2012 found that the odds of suffering cata-
strophic health expenditure were 168% higher 
in patients with cancer compared with those with 
communicable diseases.
The limitations of our study include the low 
number of study participants and the fact that 
the study was conducted at a single institute. 
Because this was a tertiary referral hospital, the 
findings of this study may not be representative 
the whole of India.
The costs associated with complex surgery for 
GI and other hepatobiliary surgeries, although 
relatively cheaper in India than in high-income 
countries, are high and often unaffordable for 
the majority of India’s population. Many people 
may be denied complex cancer care because of 
their inability to pay for services. Even though 
the Indian Government runs many schemes to 
provide subsidized care to the masses, lack of 
awareness and lack of necessary documents 
such as ration cards may cause them to forego 
health care altogether. With the increasing bur-
den of cancers requiring complex tertiary-level 
surgical care, new approaches to strengthening 
the public health care surgical system must be 
undertaken on an urgent basis in India and in 
other emerging powers.4 New structural mod-
els are needed, especially the development of 
centers of cancer surgical excellence with high 
volumes to reduce costs and improve the quality 
of care.
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